PMID- 20483885
OWN - NLM
STAT- MEDLINE
DCOM- 20100922
LR  - 20211020
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 16
IP  - 6
DP  - 2010 Jun
TI  - Memantine for cognitive impairment in multiple sclerosis: a randomized 
      placebo-controlled trial.
PG  - 715-23
LID - 10.1177/1352458510367662 [doi]
AB  - BACKGROUND: Memantine, an NMDA antagonist, is effective for moderate to severe 
      Alzheimer's disease. OBJECTIVE: Determine whether memantine improves cognitive 
      performance (CP) among subjects with multiple sclerosis (MS) and cognitive 
      impairment (CI). METHODS: This double-blind, randomized, placebo-controlled trial 
      (Clinicaltrials.gov NCT00300716) compared memantine 10 mg twice a day (4 week 
      titration followed by 12 weeks on the highest tolerated dose) with placebo. The 
      primary outcome was the change from baseline to exit on the Paced Auditory Serial 
      Addition Test (PASAT) and the California Verbal Learning Test-II (CVLT-II) Long 
      Delay Free Recall (LDFR). Secondary outcomes included additional 
      neuropsychological tests; self-report measures of quality of life, fatigue, and 
      depression; and family/caregiver reports of subjects' CI and neuropsychiatric 
      symptoms. RESULTS: The differences between the groups on the change on the PASAT 
      (placebo-memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) and on 
      CVLT-II LDFR (placebo-memantine =-0.6 words, 95% CI -2.1, 0.8; p = 0.4) as well 
      as on the other cognitive tests were not significant. Subjects on memantine had 
      no serious adverse events (AEs) but had more fatigue and neurological AEs as well 
      as, per family members' reports, less cognitive improvement and greater 
      neuropsychiatric symptoms than subjects on placebo. CONCLUSION: Memantine 10 mg 
      twice a day does not improve CP in subjects with MS, ages 18-65, without major 
      depression, who have subjective cognitive complaints and perform worse than one 
      SD below the mean on the PASAT or on the California Verbal Learning Test-II 
      (total recall or delayed free recall).
FAU - Lovera, J F
AU  - Lovera JF
AD  - Neurology, Louisiana State University Health Sciences Center, New Orleans, LA 
      70003, USA. jlover@lsuhsc.edu
FAU - Frohman, E
AU  - Frohman E
FAU - Brown, T R
AU  - Brown TR
FAU - Bandari, D
AU  - Bandari D
FAU - Nguyen, L
AU  - Nguyen L
FAU - Yadav, V
AU  - Yadav V
FAU - Stuve, O
AU  - Stuve O
FAU - Karman, J
AU  - Karman J
FAU - Bogardus, K
AU  - Bogardus K
FAU - Heimburger, G
AU  - Heimburger G
FAU - Cua, L
AU  - Cua L
FAU - Remingon, G
AU  - Remingon G
FAU - Fowler, J
AU  - Fowler J
FAU - Monahan, T
AU  - Monahan T
FAU - Kilcup, S
AU  - Kilcup S
FAU - Courtney, Y
AU  - Courtney Y
FAU - McAleenan, J
AU  - McAleenan J
FAU - Butler, K
AU  - Butler K
FAU - Wild, K
AU  - Wild K
FAU - Whitham, R
AU  - Whitham R
FAU - Bourdette, D
AU  - Bourdette D
LA  - eng
SI  - ClinicalTrials.gov/NCT00300716
GR  - K23 AT004433/AT/NCCIH NIH HHS/United States
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20100518
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - W8O17SJF3T (Memantine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Cognition Disorders/complications/*drug therapy/psychology
MH  - Depression/psychology
MH  - Double-Blind Method
MH  - Fatigue/psychology
MH  - Female
MH  - Humans
MH  - Male
MH  - Memantine/*therapeutic use
MH  - Middle Aged
MH  - Multiple Sclerosis/*complications/psychology
MH  - Neuropsychological Tests
MH  - Patient Selection
MH  - Quality of Life/psychology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
EDAT- 2010/05/21 06:00
MHDA- 2010/09/24 06:00
CRDT- 2010/05/21 06:00
PHST- 2010/05/21 06:00 [entrez]
PHST- 2010/05/21 06:00 [pubmed]
PHST- 2010/09/24 06:00 [medline]
AID - 1352458510367662 [pii]
AID - 10.1177/1352458510367662 [doi]
PST - ppublish
SO  - Mult Scler. 2010 Jun;16(6):715-23. doi: 10.1177/1352458510367662. Epub 2010 May 
      18.